Physician profile
William J Epperson
NPI 1740277508
$2,182.14
in general payments reported to CMS, 2019-2025
25 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $229 · 2020: $177 · 2021: $31.97 · 2022: $207 · 2023: $531 · 2024: $489 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,536.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $536.31 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $251.60 | 2021-2025 | |
| Lilly USA, LLC | $139.90 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Genentech USA, INC. | $134.56 | 2020 | |
| Amgen INC. | $120.03 | 2019-2024 | Prolia, Evenity, Repatha |
| Astellas Pharma US INC | $111.60 | 2019-2020 | |
| Glaxosmithkline, LLC. | $108.79 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Dexcom, INC. | $104.87 | 2023-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $104.62 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $99.36 | 2025 | Lifevest |
| Exact Sciences Corporation | $69.42 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $69.10 | 2022-2025 | |
| Daiichi Sankyo INC. | $53.55 | 2022-2024 | Injectafer |
| Astrazeneca Pharmaceuticals Lp | $52.58 | 2019 | |
| Xeris Pharmaceuticals, INC. | $35.39 | 2023-2025 | Gvoke Hypopen |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $29.68 | 2025 | Qutenza |
| Allergan, INC. | $26.39 | 2019-2020 | |
| Abbott Laboratories | $24.76 | 2023 | Freestyle Libre 3 |
| Nevro Corp. | $20.90 | 2023 | Senza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.57 | 2024 | |
| Phathom Pharmaceuticals, INC. | $17.45 | 2025 | Voquezna |
| Intuity Medical INC | $16.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $12.82 | 2023 | Eliquis |
| Merck Sharp & Dohme LLC | $12.54 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Epperson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.